Debbie Rigby takes a look at the latest in research news
Urinary incontinence (UI) is a common problem, especially in women, and it can significantly impact quality of life. This paper explores the nonpharmacologic measures (first-line) and pharmacologic options for UI, including undesirable adverse effects. The author suggests that pharmacists can make recommendations to help manage minor adverse effects in order to improve patient adherence to UI medications.
US Pharmacist. 2016;41(9):22-26.
A Canadian retrospective cohort study using administrative data from over 16 years has shown that approximately one in three patients are non-persistent to dabigatran or rivaroxaban within 6 months after drug initiation. Non-persistence with either dabigatran or rivaroxaban is significantly associated with worse clinical outcomes of stroke/TIA/death. Risk of stroke/TIA was markedly higher in non-persistent patients to dabigatran (HR 3.75) and rivaroxaban (HR 6.25) than those who continued to take their DOAC.
A meta-analysis of real-world data has concluded that current dipeptidyl peptidase 4-inhibitor or glucagon-like peptide 1 receptor agonist use is associated with a decreased risk of fracture. GLP1 receptor agonist use was associated with an increased risk of any fracture if the average daily dosage exceeded 22.5 μg per day.
British Journal of Clinical Pharmacology 2017;83(4):923–926.
Vitamin D supplementation and higher dietary calcium together are effective for fracture risk reduction. Vitamin D improves muscle strength and reduces the risk of falls. Frail older patients with low baseline levels of vitamin D (<30 nmol/L) show the highest therapeutic beneﬁt. The authors conclude that a maintenance dose of 1000 IU/day, or given as an equivalent dose weekly or monthly, is sufﬁcient for most individuals.
Australasian Journal on Ageing 2017;36(Suppl1):8–13.